On Tuesday, Nektar said that the efficacy data previously generated by Eli Lilly from rezpeg studies was miscalculated for both atopic dermatitis and psoriasis. Nektar claimed that an independent statistical firm (employed to analyze the raw data) discovered the data errors, which Lilly confirmed in writing. The correct data from the atopic dermatitis study demonstrated that 12 weeks of treatment with rezpeg, at the highest dose, resulted in a mean EASI score improvement of 83% and an EASI 75 response rate of 41%. EASI is a validated and widely used standard measurement for atopic dermatitis studies. Importantly, the corrected data showed that rezpeg provided a rapid and steep drop in EASI scores immediately after the initiation of therapy.